Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05357469

Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study

Led by M.D. Anderson Cancer Center · Updated on 2025-11-06

38

Participants Needed

1

Research Sites

211 weeks

Total Duration

On this page

Sponsors

M

M.D. Anderson Cancer Center

Lead Sponsor

N

National Institutes of Health (NIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients. In this proposed study, we will conduct a two-arm prospective, randomized wait-list controlled clinical trial to investigate the effectiveness of ST on pain and CIPN in AYAs with cancer.

CONDITIONS

Official Title

Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Both genders aged 15-39 years
  • Patients with chemotherapy-induced painful peripheral neuropathy (CIPN) with at least moderate symptoms of pain (4 or higher on a 0-10 scale) or neuropathy
  • Patients who have had cancer and are not currently receiving active treatment
  • Patients who speak English and can complete questionnaires alone or with help
  • Written informed consent obtained from adults or parents/guardians for adolescents, with assent from adolescents aged 15-17 years
Not Eligible

You will not qualify if you...

  • Inability to walk or stand without assistance or ambulatory devices
  • Bone or central nervous system metastases affecting walking, balance, or gait
  • History of other known or unknown causes of acute or chronic neuropathic or non-neuropathic pain
  • Presence of implanted intrathecal drug-delivery system, spinal cord or peripheral nerve stimulator, or certain metal implants such as pacemakers or defibrillators
  • History of epilepsy
  • Skin damage where electrodes would be placed
  • Prior scrambler therapy treatment
  • Use of pain medications for reasons other than CIPN

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

S

Salahadin Abdi, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here